Gregory Moss Sells 14,223 Shares of Evommune (NYSE:EVMN) Stock

Evommune, Inc. (NYSE:EVMN) insider Gregory Moss sold 14,223 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $22.83, for a total transaction of $324,711.09. Following the transaction, the insider owned 60,835 shares of the company’s stock, valued at approximately $1,388,863.05. This represents a 18.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Evommune Trading Down 5.1%

Shares of Evommune stock traded down $1.20 during trading hours on Monday, reaching $22.04. 451,405 shares of the company’s stock were exchanged, compared to its average volume of 416,057. The business’s 50 day moving average is $24.14. Evommune, Inc. has a fifty-two week low of $13.89 and a fifty-two week high of $33.20. The firm has a market cap of $793.70 million and a PE ratio of -2.32.

Evommune (NYSE:EVMN) last issued its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. Equities analysts predict that Evommune, Inc. will post -2.83 earnings per share for the current year.

Institutional Investors Weigh In On Evommune

Several hedge funds have recently bought and sold shares of the stock. EQT Fund Management S.a r.l. acquired a new stake in Evommune during the fourth quarter worth approximately $84,395,000. RA Capital Management L.P. bought a new position in shares of Evommune during the fourth quarter worth approximately $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC bought a new position in shares of Evommune during the fourth quarter worth approximately $32,989,000. Nan Fung Group Holdings Ltd bought a new position in shares of Evommune during the fourth quarter worth approximately $24,670,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Evommune during the fourth quarter worth approximately $22,408,000.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on EVMN shares. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Evommune in a research note on Tuesday, May 26th. Oppenheimer started coverage on shares of Evommune in a research note on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 target price for the company. Evercore reiterated an “outperform” rating and issued a $55.00 target price on shares of Evommune in a research note on Tuesday, February 10th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $48.00 target price on shares of Evommune in a research note on Friday, April 10th. Finally, Morgan Stanley raised their target price on shares of Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $49.25.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.